PBIO - InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Releases Progress Report on UltraShear Nano-CBD Launch Commercialization Program
Pressure BioSciences (OTCQB: PBIO), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables and specialty-testing services to the worldwide pharmaceuticals, biotherapeutics, nutraceuticals, cosmeceuticals, agrochemical, food & beverage, cannabis and other industries, has released an update regarding launch progress and commercialization program for its revolutionary, best-in-class Nano-CBD product; the product is being manufactured with PBIO's proprietary UltraShear(TM) technology platform. The most recent update notes that an additional five customers, representing nearly 350 retailers and more than $200,000 in incremental 2023 sales, have agreed to distribute the product. “In launching this best-in-class product, UltraShear Nano-CBD, a long-time advisor noted that a goal of placing and selling our Nano-CBD through 420 separate retailers (online or traditional brick and mortar locations) with modest monthly turnover assumptions would achieve annual incremental PBI revenues of $9 million plus,” said Pressure BioSciences director of marketing and sales John B. Hollister in the press release. “Thus, was born our ‘Drive to 420’ commercialization program. The 420 target has particular elegance, reflecting the cultural phenomenon of 4/20 as an informal holiday and rallying point for the celebration and advocacy for legalization of cannabis across diverse application areas. . . . With this second group of distributors announced, spanning Massachusetts, Illinois, Indiana and Maine, we are closing in on prospective access to 420 retail outlets within just the first month of launching this revolutionary performing product. It looks like we will need to raise the bar, as the early response to our Drive to 420 program has been fabulous. We are already discussing terms and signing up the next group of distributors across the USA and will update investors again during September.”
To view the full press release, visit https://ibn.fm/5mZIa
About Pressure BioSciences Inc.
Pressure BioSciences is a global leader in providing innovative, broadly enabling, high-pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical and agrochemical, as well as food and beverage manufacturing. The company’s products utilize both constant and alternating pressure. Its patented enabling technology platform — Pressure Cycling Technology (“PCT”) — uses alternating cycles of pressure to control biomolecular interactions, such as cell lysis and biomolecule extraction, safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counterbioterrorism applications. PBIO has recently expanded its market opportunities with the acquisition of the BaroFold(TM) patented technology platform, allowing the company to enter the biopharma contract services and GMP manufacturing equipment sector. The company has also developed the scalable and high-efficiency pressure-based UltraShear Technology platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room-temperature-stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. The company’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to its customers. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.